MUC1-Activated T-Cells for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a treatment using modified T cells to target a specific protein on cancer cells in patients with difficult-to-treat multiple myeloma. The goal is to see if these specially trained cells can help the immune system kill cancer cells more effectively. This new method for cancer treatment shows promise in treating multiple myeloma.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, patients on chronic high-dose steroids or other investigational cancer treatments are excluded, so you may need to adjust those if applicable.
Is MUC1-activated T-cell therapy safe for humans?
Clinical trials using MUC1-based vaccines have shown that they are generally safe, with some patients experiencing mild to moderate side effects. In a study of a similar T-cell therapy for multiple myeloma, the treatment was well tolerated with only two patients experiencing temporary, moderate infusion-related reactions.12345
What makes the MUC1-activated T-cells treatment unique for multiple myeloma?
What data supports the effectiveness of the treatment MUC1-Activated T-Cells for Multiple Myeloma?
Who Is on the Research Team?
Leif Bergsagel, M.D.
Principal Investigator
Mayo Clinic Hospital in Arizona
Are You a Good Fit for This Trial?
This trial is for adults over 18 with recurrent or treatment-resistant multiple myeloma that expresses MUC1. Participants must have tried at least three prior therapies, including a proteasome inhibitor, an IMiD, and a CD38 antibody. They should be in good general health with stable vital signs and able to provide consent. Pregnant or nursing individuals and those unwilling to use birth control are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lymphodepletion Chemotherapy
Patients receive cyclophosphamide intravenously over 60 minutes on days -5, -4, -3
Autologous Stem Cell Transplantation
Patients receive MUC1-activated T-cells intravenously over 10 minutes to 1 hour on day 0
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Autologous MUC1-activated T-cells
- Cyclophosphamide
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Cancer Institute (NCI)
Collaborator